Gregory W. Schafer Sells 20,000 Shares of Aduro BioTech Inc (ADRO) Stock

Aduro BioTech Inc (NASDAQ:ADRO) COO Gregory W. Schafer sold 20,000 shares of the company’s stock in a transaction dated Friday, December 1st. The shares were sold at an average price of $9.34, for a total transaction of $186,800.00. Following the transaction, the chief operating officer now owns 155,676 shares in the company, valued at approximately $1,454,013.84. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.

Aduro BioTech Inc (NASDAQ:ADRO) opened at $8.60 on Wednesday. Aduro BioTech Inc has a one year low of $6.01 and a one year high of $14.05.

Aduro BioTech (NASDAQ:ADRO) last issued its quarterly earnings data on Tuesday, October 31st. The biotechnology company reported ($0.33) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.30) by ($0.03). Aduro BioTech had a negative return on equity of 39.28% and a negative net margin of 548.92%. The business had revenue of $3.79 million during the quarter, compared to the consensus estimate of $4.04 million. During the same quarter last year, the company earned ($0.54) EPS. Aduro BioTech’s revenue for the quarter was up .0% on a year-over-year basis. analysts anticipate that Aduro BioTech Inc will post -1.28 earnings per share for the current fiscal year.

Several large investors have recently modified their holdings of ADRO. Harvard Management Co. Inc. bought a new position in shares of Aduro BioTech in the 3rd quarter worth approximately $69,418,000. JPMorgan Chase & Co. lifted its stake in shares of Aduro BioTech by 283.7% in the 2nd quarter. JPMorgan Chase & Co. now owns 372,348 shares of the biotechnology company’s stock worth $4,244,000 after purchasing an additional 275,295 shares during the period. Renaissance Technologies LLC lifted its stake in shares of Aduro BioTech by 762.1% in the 1st quarter. Renaissance Technologies LLC now owns 181,900 shares of the biotechnology company’s stock worth $1,955,000 after purchasing an additional 160,800 shares during the period. Nexthera Capital LP bought a new position in shares of Aduro BioTech in the 2nd quarter worth approximately $1,767,000. Finally, Baillie Gifford & Co. lifted its stake in shares of Aduro BioTech by 45.8% in the 2nd quarter. Baillie Gifford & Co. now owns 422,700 shares of the biotechnology company’s stock worth $4,819,000 after purchasing an additional 132,700 shares during the period. Hedge funds and other institutional investors own 45.19% of the company’s stock.

Several research firms have issued reports on ADRO. HC Wainwright set a $18.00 target price on shares of Aduro BioTech and gave the company a “buy” rating in a research note on Wednesday, November 1st. Oppenheimer began coverage on shares of Aduro BioTech in a research note on Monday, October 30th. They set a “buy” rating and a $15.00 target price on the stock. William Blair restated an “outperform” rating on shares of Aduro BioTech in a research note on Monday, October 2nd. Finally, BidaskClub cut shares of Aduro BioTech from a “hold” rating to a “sell” rating in a research note on Tuesday, August 8th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and eight have assigned a buy rating to the company. The company has an average rating of “Buy” and an average target price of $19.14.

ILLEGAL ACTIVITY NOTICE: “Gregory W. Schafer Sells 20,000 Shares of Aduro BioTech Inc (ADRO) Stock” was originally reported by StockNewsTimes and is the property of of StockNewsTimes. If you are reading this article on another website, it was copied illegally and republished in violation of U.S. and international copyright legislation. The original version of this article can be accessed at https://stocknewstimes.com/2017/12/06/gregory-w-schafer-sells-20000-shares-of-aduro-biotech-inc-adro-stock-2.html.

About Aduro BioTech

Aduro Biotech, Inc is an immunotherapy company, which focuses on the discovery, development and commercialization of therapies that manage the treatment of various diseases, including cancer. The Company’s product candidates from its Live, Attenuated, Double-Deleted (LADD) Listeria monocytogenes, Stimulator of Interferon Genes Pathway Activator, and B-select monoclonal antibody platforms are designed to stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies, as well as other immunotherapies.

Insider Buying and Selling by Quarter for Aduro BioTech (NASDAQ:ADRO)

Receive News & Ratings for Aduro BioTech Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aduro BioTech Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply